188 related articles for article (PubMed ID: 1372757)
1. Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors.
Bajorin DF; Herr H; Motzer RJ; Bosl GJ
Semin Oncol; 1992 Apr; 19(2):148-58. PubMed ID: 1372757
[TBL] [Abstract][Full Text] [Related]
2. Reassessment of the role of adjunctive surgical therapy in the treatment of advanced germ cell tumors.
Carter GE; Lieskovsky G; Skinner DG; Daniels JR
J Urol; 1987 Dec; 138(6):1397-401. PubMed ID: 2446018
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy of advanced testicular cancer.
Williams SD; Loehrer PJ; Einhorn LH
Semin Urol; 1984 Nov; 2(4):230-7. PubMed ID: 6209762
[No Abstract] [Full Text] [Related]
4. Vinblastine, actinomycin D, bleomycin, cyclophosphamide and cis-platinum for advanced germ cell testis tumors: Brazilian experience.
Srougi M; Simon SD; de Góes GM
J Urol; 1985 Jul; 134(1):65-9. PubMed ID: 2409300
[TBL] [Abstract][Full Text] [Related]
5. [Chemotherapeutic effectiveness in malignant testicular tumors at advanced stages. Preliminary results of the VAB VI program].
Chiricuţă I; Ghilezan N
Rev Chir Oncol Radiol O R L Oftalmol Stomatol Chir; 1985; 34(6):455-68. PubMed ID: 2421373
[No Abstract] [Full Text] [Related]
6. Early resection of residual tumor during cisplatin, vinblastine, bleomycin combination chemotherapy in stage III and bulky stage II nonseminomatous testicular cancer.
Pizzocaro G; Salvioni R; Pasi M; Zanoni F; Milani A; Pilotti S; Monfardini S
Cancer; 1985 Jul; 56(2):249-55. PubMed ID: 2408728
[TBL] [Abstract][Full Text] [Related]
7. Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors.
Kundu SD; Feldman DR; Carver BS; Gupta A; Bosl GJ; Motzer RJ; Bajorin DF; Sheinfeld J
J Urol; 2015 Feb; 193(2):513-8. PubMed ID: 25150639
[TBL] [Abstract][Full Text] [Related]
8. Value of retroperitoneal lymph node dissection in advanced testicular seminoma.
Kamat MR; Kulkarni JN; Tongaonkar HB; Ravi R
J Surg Oncol; 1992 Sep; 51(1):65-7. PubMed ID: 1381455
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection.
Toner GC; Panicek DM; Heelan RT; Geller NL; Lin SY; Bajorin D; Motzer RJ; Scher HI; Herr HW; Morse MJ
J Clin Oncol; 1990 Oct; 8(10):1683-94. PubMed ID: 2170590
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy for germ cell tumors.
Motzer RJ; Bosl GJ
Urol Clin North Am; 1987 May; 14(2):389-98. PubMed ID: 2437682
[TBL] [Abstract][Full Text] [Related]
11. The extent of surgery after chemotherapy for advanced germ cell tumors.
Freiha FS; Shortliffe LD; Rouse RV; Mark JB; Hannigan JF; Aston D; Spaulding JT; Williams RD; Torti FM
J Urol; 1984 Nov; 132(5):915-7. PubMed ID: 6208386
[TBL] [Abstract][Full Text] [Related]
12. Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis.
Logothetis CJ; Samuels ML; Selig D; Swanson D; Johnson DE; von Eschenbach AC
J Clin Oncol; 1985 Mar; 3(3):326-35. PubMed ID: 2579213
[TBL] [Abstract][Full Text] [Related]
13. Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT).
de Bono JS; Paul J; Simpson A; Anthoney A; Kirk D; Underwood M; Graham J; Kaye SB
Br J Cancer; 2000 Aug; 83(4):426-30. PubMed ID: 10945485
[TBL] [Abstract][Full Text] [Related]
14. [Advanced non-seminoma germinal tumors of the testicle. Therapeutic strategy and method of action of chemotherapy].
Bassoulet J; Raoul Y; Garetta L
Ann Urol (Paris); 1986; 20(1):35-42. PubMed ID: 2423016
[TBL] [Abstract][Full Text] [Related]
15. Management of the postchemotherapy residual mass.
Sheinfeld J; Bajorin D
Urol Clin North Am; 1993 Feb; 20(1):133-43. PubMed ID: 8381994
[TBL] [Abstract][Full Text] [Related]
16. [Infusion of high doses of platidiam in the treatment of patients with germ cell testicular tumors].
Tiuliandin SA
Vopr Onkol; 1990; 36(1):89-92. PubMed ID: 1689528
[TBL] [Abstract][Full Text] [Related]
17. Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer.
Fosså SD; Aass N; Ous S; Høie J; Stenwig AE; Lien HH; Paus E; Kaalhus O
J Urol; 1989 Nov; 142(5):1239-42. PubMed ID: 2478726
[TBL] [Abstract][Full Text] [Related]
18. Residual mass after chemotherapy for seminoma: changing concepts of management.
Herr HW; Bosl G
J Urol; 1987 Jun; 137(6):1234-5. PubMed ID: 2438431
[TBL] [Abstract][Full Text] [Related]
19. Optimal management of germ cell cancer: more a matter of expertise than of chemotherapy regimen.
de Wit R
J Urol; 2015 Feb; 193(2):391-3. PubMed ID: 25447105
[No Abstract] [Full Text] [Related]
20. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
